



In Silico Screening of Cinnamon (*Cinnamomum burmannii*) Bioactive Compounds as Acetylcholinesterase Inhibitors

Zatta Yumni Ihdhar Syarafina^a, Mega Safithri^{a,*}, Maria Bintang^a, Rini Kurniasih^a

^a Department of Biochemistry, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia

*Corresponding author: safithri@apps.ipb.ac.id

<https://doi.org/10.14710/jksa.25.3.97-107>

Article Info

Article history:

Received: 18th December 2021

Revised: 2nd March 2022

Accepted: 8th March 2022

Online: 31st March 2022

Keywords:

Alzheimer;

acetylcholinesterase;

cinnamon; molecular docking

Abstract

Alzheimer's is a progressive and neurodegenerative disease that mainly affects people aged 65 years and older. The pathophysiology of Alzheimer's is possibly related to the depletion of the neurotransmitter acetylcholine (ACh) due to beta-amyloid plaques and neurofibrillary tangles. Secondary metabolites found in cinnamon bark (*Cinnamomum burmannii*) have the potential as anticholinesterases to treat Alzheimer's symptoms. This study aimed to identify the potency of bioactive compounds from cinnamon bark as AChE inhibitors in silico through analysis of binding energy, inhibition constants, and types of interactions. The research was conducted by screening virtually 60 test ligands using the PyRx program and molecular docking using the Autodock Tools program. The results of the ligand-receptor interaction analysis showed that 12 of the 15 tested ligands had potential as AChE inhibitors. Epicatechin and medioresinol are the ligands with the best potential for AChE inhibition with affinity close to the natural ligand or donepezil. Epicatechin has a binding energy of -10.0 kcal/mol and inhibition constant of 0.0459 M, with four hydrogen bonds and seven hydrophobic bonds. Meanwhile, medioresinol has -9.9 kcal/mol binding energy and inhibition constant of 0.0543 M, with one hydrogen bond and thirteen hydrophobic bonds.

1. Introduction

Alzheimer's disease is a neurodegenerative disorder characterized by the death of brain cells, causing memory loss and cognitive decline. This disease is the most common cause of dementia in people aged 65 years and older. Alzheimer's disease causes brain shrinkage as the number and interactions between nerve cells are reduced [1]. This condition is characterized by progressive memory loss, impaired memory formation, decreased intellectual function and speaking skills, and personality changes [2]. According to Alzheimer's Disease International [3], there were 55 million people worldwide with dementia in 2019. This number is expected to increase to 78 million in 2030 and 139 million in 2050. According to Alzheimer's Indonesia [4], the prevalence of Alzheimer's disease in Indonesia in 2016 reached 1.2 million people, and this number is expected to increase to 4 million in 2050. This shows that people living with Alzheimer's are increasing every year.

Several hypotheses regarding the pathophysiology of Alzheimer's disease include the cholinergic hypothesis, beta-amyloid (A β) plaque formation, tau protein, oxidative stress, and inflammation. Acetylcholine (ACh) is the primary neurotransmitter of the cholinergic system, which can be hydrolyzed to choline and acetic acid catalyzed by acetylcholinesterase (AChE). The cholinergic hypothesis assumes that AChE inhibition can prevent ACh hydrolysis, leading to increased ACh levels at cholinergic synapses [5]. Therapeutic attempts developed to treat Alzheimer's are inhibiting cholinesterase activity, thereby decreasing ACh levels at synaptic junctions. Some cholinesterase inhibitors approved by the US Food and Drug Administration for treating Alzheimer's disease are donepezil, rivastigmine, galantamine, and tacrine. These four drugs have different pharmacological properties in inhibiting AChE [6].

Alzheimer's drugs can cause several side effects: hepatotoxicity, nausea, vomiting, diarrhea, fainting, and bradycardia [7]. As a result, biomedical innovation is required to develop and utilize alternative AChE inhibitor compounds with fewer side effects and are safer and effortless to obtain. One of the possible alternative sources of AChE inhibitors is the cinnamon bark and leaves (*Cinnamomum burmannii*). The main components contained in *Cinnamomum* sp. are cinnamaldehyde, cinnamic acid, cinnamyl acetate, eugenol, caryophyllene, caryophyllene oxide, -cubebene, -terpineol, coumarin, and camphor. Cinnamon bark essential oil contains high cinnamaldehyde content, while the leaf contains mainly eugenol as the main compound [8].

One of the computational drug discovery methods that have been developed is virtual screening. Virtual screening is a computational technique for identifying the potency of many bioactive compounds against specific macromolecules such as proteins [9]. Virtual screening offers short processing times and cost-effectiveness involved in screening compounds and does not require the physical presence of molecules [10]. Virtual screening is conducted using the PyRx program, which can perform molecular docking quickly and accurately. Vina Wizard-based virtual screening results were evaluated based on the binding free energy [11].

Cinnamon leaves and bark contain bioactive compounds that have the potential as antibacterial, antifungal, antioxidant, antidiabetic, anticancer, anticholinesterase, and hypouricemic [12]. According to Okello and Mather [13], the inhibitory activity of AChE in vitro indicates that green tea epicatechin has inhibitory effects on AChE. The interaction that occurs in the bioactive compound of cinnamon as anticholinesterase in vitro has not been studied yet. This study aimed to determine bioactive compounds found in the bark and leaves of cinnamon (*Cinnamomum burmannii*) in silico using virtual screening and molecular docking methods. These methods were used to predict the interaction of the bioactive compounds of cinnamon bark and leaves as inhibitors of the AChE enzyme through the analysis of binding free energy, inhibition constants, and ligand interactions with AChE receptors (PDB ID: 4EY7).

2. Methods

2.1. Tools and Materials

The tools used in the research were computer hardware with specifications of TOSHIBA Intel Core i3, 2 GB RAM with Windows 7 operating system. Molecular docking simulation using AutoDock Tools software version 1.5.6, Discovery Studio Visualizer version 16.1.0.15350 (free), Ligplot+ version 1.5.4, PyRx, and PyMOL version 4.60. The material used was the three-dimensional structure of the enzyme AchE, complexed with donepezil was downloaded from the RCSB Protein Data Bank database (<https://www.rcsb.org/>) [14] with code 4EY7 on October 14, 2020. Sixty three-dimensional structures of cinnamon bioactive compounds and natural ligands donepezil were downloaded from the

PubChem database (accessed on October 14, 2020) in *.sdf format (Table 1).

Table 1. Active compounds of cinnamon bark and leaves

Ligands	
Donepezil (reference)	Eugenol
Quercetin	Terpinen-4-Ol
Epicatechin	D-Limonene
Medioresinol	Gamma-terpinene
(+)-syringaresinol	2-Carene
Gamma-Eudesmol	trans-cinnamic acid
Proanthocyanidins	Alpha-terpineol
(+)-ledene	Cinnamic acid
Alpha-calacorene	Camphor
epi-bicyclosesquiphellandrene	Alpha-pinene
Gamma-Muuroleone	Eucalyptol
Guaiol	(-)-Beta-pinene
Calarene	1,8 cineole
Gamma-cadinene	Borneol
Ylangene	Cinnamyl alcohol
(-)-spathulenol	Cinnamaldehyde
Alpha-Cubebene	Linalool
(Z)-nerolidol	Benzenepropanal
Aromadendrene	Syringaldehyde
Alpha-muuroleone	Benzaldehyde
Caryophyllene Oxide	(Z)-nerolidol
Epicubeno	Linoleic Acid
Elemol	Gamma-elemene
Copaene	Bornyl acetate
Alpha-amorphene	Humulene
Beta-guaiene	Alpha-humulene
Santalene	Alpha-terpinyl acetate
Beta-caryophyllene	Cinnamyl Acetate
Isoledene	Cinnamyl alcohol
Caryophyllene	Coumarin
p-cymene	

2.2. Preparation of receptor structure and stability

The structure used was the three-dimensional structure of AChE (GDP ID: 4EY7) in *.pdb format. AChE consisted of two subunits, A and B, joined by two disulfide bonds from the cysteine residue to form a protein homodimer [15]. The three-dimensional structure of the human AChE enzyme forms a complex with the crystallized donepezil. Several molecules attached to the enzyme structure were 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine (Donepezil), 2-acetamido-2-deoxy-beta-D-glucopyranose, 1,2-ethanediol, and the nitrate ion. Donepezil is a natural ligand functioning as an inhibitor of the AChE enzyme. The enzyme with this code has a resolution of 2.35. The resolution of the protein crystal structure is declared good if the value is not more than

2.70 [16]. The structure was prepared using the Discovery Studio Visualizer program by removing water molecules and other ligands which still attached to the structure. Polar hydrogen atoms were added to the structure. The prepared structure was saved in *.pdbqt format using AutoDock Tools version 1.5.6 [17].

The stability of the three-dimensional receptor structure was analyzed online with PROCHECK on <http://servicesn.mbi.ucla.edu/> [18]. The three-dimensional structure of the receptor downloaded from PDB was uploaded to the page and clicked on runprocheck.

2.3. Ligand structure preparation

The three-dimensional structure of the test ligand compound in *.sdf format was downloaded from the PubChem website (<https://pubchem.ncbi.nlm.nih.gov/>) and converted using Discovery Studio into *.pdb format. Furthermore, the ligand was optimized using AutoDock Tools version 1.5.6 with the addition of hydrogen bonds and saved in *.pdbqt format.

2.4. Virtual screening

Sixty optimized and pre-prepared ligands were attached to AChE through virtual screening using PyRx software. Virtual screening was conducted on a grid box with the coordinates of the optimum validation results based on AutoDock Vina. The resulting binding free energy and Root Mean Standard Deviation (RMSD) values were then sorted based on the smallest to the most significant binding free energy values for the next step.

2.5. Prediction of physicochemical and ligand toxicity

The physicochemical of ligand were predicted online by accessing the site <http://www.scfbio-iitd.res.in/software/drugdesign/lipinski.jsp> [19]. The prediction of online-based ligand toxicity was carried out using admetSAR on the http://lmmd.ecust.edu.cn/admet_sari/predict/ by uploading the SMILES structure of the predicted ligand [20].

2.6. Molecular docking validation

Validation was performed by specifying the grid box $x = 38$, $y = 20$, $z = 28$; central point coordinates at $x = -13,988$, $y = -43.906$, $z = 27109$; and the exhaustiveness value was set at 20 in the natural ligand using AutoDockTool v.1.5.6. and AutoDock Vina. Validation was repeated 20 times to obtain the $RMSD < 2$. The grid box was created by adjusting the dimensions of the natural ligand-binding pocket (donepezil) in AChE by selecting the center on the ligand in AutoDockTool v.1.5.6. RMSD values were checked using the Discovery Studio Visualizer 2016 program. Molecular docking is declared valid if the RMSD value is less than 2 [21].

2.7. Molecular docking

The structure of ligands and receptors in *.pdbqt format was stored in the same vina folder. The docking was done in the best grid box area as validation results using the AutoDock Vina program by running CMD

(Command Prompt) with the command “vina.exe –config config.txt –log log.txt”. The molecular docking result was in log.txt form, containing the binding free energy and RMSD value and a document in *.pdbqt format [21].

2.8. Analysis and visualization of molecular docking results

Analysis of the results of the binding of the ligand molecule with the AChE enzyme in the form of bonding free energy in log.txt format. Based on this value, the value of the inhibition constant was obtained based on the equation $G_{bind} = -RT \ln K_i$ (ΔG_{bind} = binding free energy (kcal/mol), $R = 1.986 \times 10^{-3}$ kcal/mol.K, $T = 298.15$ K [22]. In these results, hydrogen bond and hydrophobic interactions were visualized using LigPlot+ v.1.5.4 (2D) and PyMol v.4.60 (3D).

3. Results and Discussion

3.1. Receptor structure and stability




Figure 1. Structure of complexed AChE with donepezil [23]

The stability of the receptor structure was analyzed to determine the feasibility of the receptor in the molecular docking process using the Ramachandran diagram. The diagram shows the distribution of amino acids in a protein that can be classified into four quadrants. The red color in the Ramachandran diagram shows residues in the most favored regions, and the yellow color shows residues in the additionally allowed regions. The orange color shows the residues in the generously allowed regions, and the white color shows the residues in the prohibited regions (disallowed regions). All amino acids are prohibited in this region, excluding glycine [24]. The amino acid glycine has only a hydrogen atom and no reactive carbon atom, which can cause many of the steric movements in the Ramachandran diagram; consequently, these amino acids have a low steric effect against other amino acids residues [25]. The structure of complexed AChE with donepezil is depicted in Figure 1.

The Ramachandran diagram analysis shows that the enzyme with code 4EY7 has amino acid residues of 90.9% in the most favored regions, 8.9% in the additionally allowed regions, 0.0% in the generously

allowed, and 0.0% in the disallowed regions. A protein structure is declared good if the number of plots of non-glycine amino acid residues present in the most favored regions is more than 90% and in the disallowed regions less than 15% [26]. The AChE enzyme can be declared stable and of reasonably good quality. Ramachandran diagram of the AChE enzyme from the previous study can be seen in Figure 2.




Figure 2. Ramachandran diagram of the AChE enzyme [18]

3.2. Virtual screening

Table 2. The best compounds from virtual screening

Ligand	Binding free energy (kcal/mol)
Donepezil (natural and reference)	-12.2
Quercetin	-10.2
Epicatechin	-10.0
Medioresinol*	-9.9
(+)-Syringaresinol*	-9.8
Gamma-eudesmol	-9.7
Proanthocyanidins	-9.5
(+)-Ledene	-9.4
(Alpha-calacorene)	-9.4
epi-bicyclosquiphellandrene	-9.1
Cinnamyl acetate*	-7.5
Coumarin*	-7.4
Cinnamic acid*	-7.1
Cinnamyl alcohol*	-6.6
Cinnamaldehyde	-6.6
Syringaldehyde*	-6.4

*, typical compound of cinnamon based on IJAH (Indonesian Jamu Herbs)

The virtual screening results were evaluated based on the order of binding free energy and RMSD [11]. The value of free binding energy (ΔG_{bind}) indicates the stability of a ligand to bind to the receptor. The more negative the G_{bind} value, the better the stability level, so that the bond between the ligand and the receptor is getting stronger [27]. The best ligand resulting from virtual screening is the ligand with the highest binding free energy close to the binding free energy value of the

reference ligand. Donepezil has a binding free energy of -12.2 kcal/mol, indicating that the reference ligand has the most robust and most stable affinity for the receptor compared to all test ligands.

Of the 60 ligands, 15 ligands passed the virtual screening based on the binding free energy, with 9 of them having binding free energy approaching the donepezil reference ligand, which is less than -9.0 kcal/mol (Table 2). Meanwhile, the other six compounds are typical cinnamon compounds based on the IJAH (Indonesian Jamu Herbs) website (<http://ijah.apps.cs.ipb.ac.id>) will be determined their potential as AChE inhibitors.

3.3. Prediction of physicochemical and ligand toxicity

The physicochemical analysis is a crucial step used in analyzing the effectiveness of oral drugs. The effectiveness can be predicted based on Lipinski's rule or Lipinski's Rule of Five. Lipinski's rule states that an oral drug compound has excellent absorption and permeation if it has a molecular mass of less than 500 Daltons, a Log P value of less than 5, the number of hydrogen bond donors less than 5, no more than 10 hydrogen bond acceptors, and the value of refractivity molar in the 40–130 range [28].

The molecular mass is related to the absorption of the drug in the body. The smaller the relative atomic mass of a compound, the easier it will be for the compound to passively diffuse through cell membranes in the small intestine and into target tissues [29]. The number of donors and acceptors of hydrogen ligands affects the absorption rate of the active compound into the body. A large number of hydrogen bond donors can reduce the ability of the molecule to penetrate the membrane bilayer. Compounds with many hydrogen bond donors and acceptors will form stronger hydrogen bonds to solvents (water) than to the lipophilic environment in the cell membrane [28].

The partition coefficient value (Log P) represents the compound's solubility in octanol or water, ideally below 5. Ivanovic [30] stated that lipophilicity, expressed by Log P, is related to the rate of drug distribution in the body. A positive value for Log P means that the compound has a higher affinity for the nonpolar phase; therefore, the drug will bind strongly to lipids and have difficulty penetrating biological membranes. This phenomenon makes the compound unable to bind to the receptor. The value of the molar refractivity shows the size of the spread of a derived molecule per one mole of the compound. A compound has potential as an oral drug if it has a molar refractivity value ranging from 40 to 130 [31]. The results of Lipinski's rule for active compounds in cinnamon bark and leaves are shown in Table 3. According to Lipinski's Rule of Five, the compounds that do not violate more than two of the rules are potential candidates for oral drugs. All ligands complied with Lipinski's rules except for proanthocyanidins which violated four rules; therefore, these compounds were not classified as good oral drug candidates. From the results, only 14 meet the five criteria of Lipinski's rule so that they could be used as drug candidates.

Table 3. The results of the stability analysis of the test ligands using Lipinski’s rule

Ligand	Lipinski’s rule				
	Molecular mass	Hydrogen bond donor	Hydrogen bond acceptor	Log P	Molar refractivity
Donepezil (reference)	350	0	4	1.106	87.089
Quercetin	302	5	7	2.011	74.050
Epicatechin	290	5	6	1.546	72.623
Medioresinol	388	2	7	3.199	100.236
(+)-Syringaresinol	418	2	8	3.203	106.788
Gamma-eudesmol	222	1	1	4.064	68.297
Proanthocyanidins	592	9	12	3.298	148.272
(+)-Ledene	204	0	0	4.415	64.583
(Alpha-calacorene)	200	0	0	4.541	67.026
epi-bicyclosesquiphellandrene	204	0	0	4.581	66.673
Cinnamyl acetate	176	0	2	2.263	52.109
Coumarin	146	0	2	1.619	41.111
Cinnamic acid	148	1	2	1.784	43.112
Cinnamyl alcohol	134	1	1	1.692	42.562
Cinnamaldehyde	132	0	1	1.899	41.540
Syringaldehyde	182	1	4	1.222	46.598

Drug development determines the level of toxicity based on the virtual structure of the compound. This process ensures compounds that have the potential as drugs can work effectively without causing damage to organs. Toxicity is the ability of a compound to cause harmful effects when it enters the body. Toxicity prediction used three parameters: inhibition of Human Ether-A-Go-Go Related Gene (hERG), carcinogenicity, and acute oral toxicity (Table 4). Prediction results of

hERG inhibition indicate that donepezil is an hERG strong inhibitor.

Meanwhile, the other test ligands were classified as weak hERG inhibitors. hERG is a gene encoding a pore-forming subunit in K⁺ channel protein that plays a role in repolarizing cardiac action potentials. Blockage or disruption of K⁺ channels found in cardiac cells can cause cardiac arrhythmias and be toxic to the heart [32].

Table 4. The results of the predictive analysis of ligand toxicity

Ligand	Inhibition of Human Ether-A-Go-Go Related Gene (hERG)		Carcinogenic		Acute oral toxicity	
	Category	Score	Category	Score	Category	Score
Donepezil (reference)	Strong inhibitor	0.5386	Non-carcinogenic	0.9528	III	0.5250
Quercetin	Weak inhibitor	0.9781	Non-carcinogenic	0.9450	II	0.7348
Epicatechin	Weak inhibitor	0.9666	Non-carcinogenic	0.9539	IV	0.6433
Medioresinol	Weak inhibitor	0.9418	Non-carcinogenic	0.8939	III	0.6630
(+)- Syringaresinol	Weak inhibitor	0.9494	Non-carcinogenic	0.8036	III	0.6169
Gamma-eudesmol	Weak inhibitor	0.8830	Non-carcinogenic	0.8501	IV	0.4811
(+)-Ledene	Weak inhibitor	0.9643	Non-carcinogenic	0.7765	III	0.8165
Alpha-calacorene	Weak inhibitor	0.9438	Non-carcinogenic	0.7062	III	0.6186
epi-bicyclosesquiphellandrene	Weak inhibitor	0.8089	Non-carcinogenic	0.7928	III	0.7969
Cinnamyl acetate	Weak inhibitor	0.9475	Non-carcinogenic	0.6061	III	0.9005
Coumarin	Weak inhibitor	0.8702	Non-carcinogenic	0.9412	II	0.7019
Cinnamic acid	Weak inhibitor	0.9620	Non-carcinogenic	0.5927	III	0.8487
Cinnamyl alcohol	Weak inhibitor	0.8730	Non-carcinogenic	0.5332	III	0.8179
Cinnamaldehyde	Weak inhibitor	0.9241	Non-carcinogenic	0.5786	III	0.8687
Syringaldehyde	Weak inhibitor	0.9418	Non-carcinogenic	0.8939	III	0.6630

Carcinogenicity is the ability of a compound to cause new tissue growth or neoplasia [33]. The International Agency for Research on Cancer (IARC) classifies carcinogenicity into four groups: I (carcinogenic), II-A (probably carcinogenic), II-B (possibly carcinogenic), III (unclassified), and IV (non-carcinogenic) [34]. The carcinogenicity prediction results showed that the reference and test ligands were included in the non-carcinogenic category, so all of these ligands are safe to be used as drugs.

Acute oral toxicity refers to side effects that occur in a short time due to single or repeated doses of a drug for 24 hours [35]. Acute oral toxicity is based on the Lethal Dose 50 (LD₅₀) value, the amount of the chemical administered orally in mg/kg body weight, causing the death of 50% of the experimental animal population [36]. According to the United State Environmental Protection Agency (US EPA), acute oral toxicity of compounds is classified into four categories based on the LD₅₀ value. Category I (LD₅₀ 50 mg/kg), category II has (LD₅₀ >500 mg/kg), category III (LD₅₀ 5000 mg/kg), and category IV (LD₅₀ 5000 mg/kg) [37]. Prediction results of acute oral toxicity showed that quercetin and coumarin were included in category II (moderately toxic), and almost all test ligands were included in category III (slightly toxic) and IV (non-toxic). Based on these results, quercetin and coumarin are predicted to be toxic to the digestive tract, which can cause damage to cells and organ tissues in the body, so they are not safe to be used as drug candidates.

3.4. Molecular docking validation

Validation was conducted to obtain a grid box that includes the active site of the AChE enzyme as a binding target by re-docking the natural ligand to the AChE enzyme. The validation parameters are based on the RMSD value, indicating the degree of deviation of the ligand re-docking results from the crystallographic ligands at the same binding site. The lower the RMSD value, the closer the ligand was to the native conformation, and this is considered a good position. The RMSD value is confirmed to be valid if it is less than or equal to 2. RMSD values greater than 2.5 indicate that the ligand molecule is far shifted from the docking

position; thus, the ligand does not bind to the receptor's active site [38].

The validation results showed that the binding side with the best binding pose was at position $x = 38$; $y = 20$; $z = 28$ and center area $x = 13.988$; $y = -43.906$; $z = 27.109$ (Figure 3). The average RMSD value obtained in 20 repetitions was less than 2. The molecular docking is declared valid if the RMSD value is 2.00 [39]. The validation results indicate that the grid box area used for docking is valid and can be used for molecular docking of the test ligand because it has an RMSD value below 2Å [39].




Figure 3. Molecular docking validation 20 times with natural ligand (donepezil) (yellow) and the validated ligand (gray)

3.5. Molecular docking and visualization of molecular docking results

Molecular docking simulations can predict interactions, binding free energies, and conformation of protein-ligand complexes. The ligand binds to the target protein's active site to generate an optimal interaction pose and docking score based on the binding free energy. This study utilized a targeted docking method carried out on the active site area of the receptor that binds to a particular ligand; therefore, it only predicts the interaction between the ligand and the active site of the receptor [40]. Two-dimensional visualization of the interaction between cinnamon compounds with hydrogen bonds and their hydrophobicity with receptor amino acid residues can be seen in Figure 4.




Figure 4. Two-dimensional molecular docking results in (a) *epicatechin*, (b) *medioresinol* [41]

AChE inhibitors can inhibit AChE by interacting with the active sites of the CAS catalytic triad (Ser203, Glu334, and His447) or the Peripheral Anionic Site (PAS) sites, namely Tyr72, Asp74, Tyr124, Ser125, Trp286, Tyr337, and Tyr341, or by binding to both sides CAS and PAS [42]. The active sites of AChE, namely Catalytic Anionic Site (CAS) and Peripheral Anionic Site (PAS), play a prominent role in ligand binding. PAS propels ligands into the gorge, particularly positively charged species such as choline. Once the ligand enters the gorge, the acyl binding site and choline-binding site are located near the catalytic triad, assisting in positioning the ligand for catalysis by CAS [43]. CAS of serine, glutamic acid, and histidine residues, also known as the catalytic triad. The primary catalytic function performed by AChE is the hydrolysis of the neurotransmitter ACh into acetic acid and choline [44].

Epicatechin and medioresinol have more potential as AChE inhibitors because they have a low binding free energy value and interact more than the other test compounds. Epicatechin has the highest affinity value of -10.0 kcal/mol (Table 5).

Epicatechin, a polyphenol group compound, possibly has a more negative ΔG_{bind} value than other test ligands because it has more hydrogen bonds in the structure of the compound. The value of the binding free energy of a ligand toward the receptor is influenced by hydrogen bonds and hydrophobic bonds [45]. The distance between a hydrogen bond affects the free energy of the bond present. The close distance of the

hydrogen bond between the ligand and the target amino acid residue leads to a strong and stable interaction that occurs. According to Jeffrey [46], hydrogen bonds are divided into several criteria according to the interaction distance, namely strong, medium, and weak hydrogen bonds. Strong hydrogen bonds have an interaction distance of < 2.5, medium (almost electrostatic) hydrogen bonds have an interaction distance of 2.5–3.2, and weak hydrogen bonds have an interaction distance of 3.3–4.0. The hydrogen-bonding distance in the test ligands and receptors is in the weak and moderate categories.

In contrast to medioresinol, the structure of this compound has fewer hydroxyl groups than epicatechin. Each hydrogen bond increases the affinity by 0.48 to 1.55 kcal/mol for neutral bonds and 2.39 to 4.78 kcal/mol for charged bonds or salt bridges [47]. In addition, epicatechin compounds also bind to two amino acid residues at the CAS catalytic site and partly bind to the PAS site. Meanwhile, medioresinol only binds to the PAS active site. Dual binding inhibitors such as donepezil bind to CAS and PAS sites, thus exhibiting potent AChE inhibitory activity [5]. Inhibition of the CAS of AChE can reduce the degradation of ACh. At the same time, inhibition of the PAS site can reduce the formation of A β plaques. PAS can form stable complexes with beta-amyloid peptides, thereby accelerating oligomerization of A β peptides and senile plaque aggregation that will lead to Alzheimer's [48].

Table 5. The results of the two-dimensional visualization of the ligand to the receptor

Ligand	Binding free energy (kcal/mol)	Hydrogen bonded amino acid residue	Bond length (Å)	Hydrophobic bonded amino acid residue
Donepezil (reference)	-12.3	Phe295	2.80	Ser203 , His447 , Glu202, Trp86, Trp286, Phe338, Tyr337, Ser293, Tyr72, Tyr124, Tyr341, Gly121, Gly448, Val294
		Gly121	3.23	
Epicatechin	-10.0	Gly122	2.87	Ser203 , Tyr341, Tyr337, Phe338, Trp86, Gly121, Tyr124, Tyr72, Trp286, Tyr341, Asp74, Trp86, Gly121
		Tyr124	3.02	
		Ser203	3.09	
Medioresinol	-9.9	Ser125	2.88 2.82	Gly126, Gly120, Tyr133, Glu202, Phe338, Tyr337, Tyr124, Tyr72, Trp286, Tyr341, Asp74, Trp86, Gly121
(+)-Syringaresinol	-9.8			Gly121, Tyr337, Tyr124, Tyr341, Tyr72, Trp286, Leu289, Ser293, Phe297, Phe295, Gly122, His447 , Phe338
Gamma- eudesmol	-9.7	Glu202	3.30	Tyr133, Gly121, Gly122, Tyr124, Phe297, Phe338, Tyr337, His447 , Trp86, Gly448, Gly121
		Ser203	2.70	
(+)-Ledene	-9.4			Ser203 , Tyr341, Tyr337, Phe338, Trp86, Glu202, Gly121, His447 , Gly122, Phe297, Tyr124
Alpha-calacorene	-9.4			Phe338, Tyr337, Asp74. Ser125, Tyr124, Trp86, Gly448, Glu202, Tyr341
epi-bicyclosiquiphellandrene	-9.2			Tyr124, Gly121, Glu202, His447 , Tyr337, Phe338, Asp74, Ser125, Trp86
Cinnamyl acetate	-7.5	Arg296	3.31	Val294, Phe297, Tyr341, Tyr337, His447 , Phe338, Trp286
		Phe295	2.90	
Cinnamic acid	-7.1	Tyr337	2.84	Tyr341, Asp74, Trp86, His447 , Glu202, Gly448,
Cinnamyl alcohol	-6.6	Arg296	2.96	Val294, Phe297, Phe295, Tyr124, Tyr341, Tyr337, Phe338, Trp286
			3.10	
Cinnamaldehyde	-6.6	Tyr337	2.97	Asp74, Tyr341, Gly121, Glu202, Gly448, Trp86
			2.82	
Syringaldehyde	-6.4	Ser203	3.06	Gly121, His447 , Phe295, Phe297, Phe338, Tyr124, Trp86
		Gly122	2.96	

3.6. Antibacterial activity of fractions

The molecular docking result parameter is binding free energy. Molecular docking results obtained from AutoDock Vina (Table 6) indicate that the value of ΔG_{bind} and the inhibition constant (K_i) of the test ligand is greater than that of the reference ligand donepezil. Donepezil has a ΔG_{bind} of -12.3 kcal/mol, indicating that all the tested ligands can bind to the receptor, although not as strongly as donepezil.

Table 6. Binding free energy and ligand inhibition constant

Ligand	Binding free energy (kcal/mol)	Inhibition constant (μM)	Number of hydrogen bonds	Number of hydrophobic bonds
Donepezil (reference)	-12.3	0.0009	1	14
Epicatechin	-10.0	0.0459	4	7
Medioresinol	-9.9	0.0543	1	13
(+)-syringaresinol	-9.8	0.0644	0	13
Gamma-eudesmol	-9.7	0.0762	2	11
(+)-ledene	-9.4	0.1265	0	11
(Alpha-calacorene)	-9.4	0.1265	0	9
Epibicyclosquiphe llandrene	-9.2	0.1774	0	9
Cinnamyl acetate	-7.5	3.1359	2	7
Cinnamic acid	-7.1	6.1643	1	6
Cinnamyl alcohol	-6.6	14.3482	1	8
Cinnamaldehyde	-6.6	14.3482	1	6
Syringaldehyde	-6.4	20.1169	2	7

The binding free energy represents the most negligible energy used by the receptor to interact with the ligand. The smaller the ΔG_{bind} value leads to a stronger binding affinity between the receptor and the ligand, causing the compound to be better at inhibiting the receptor. The value of ΔG_{bind} is influenced by hydrogen bonding and hydrophobicity. Ligands with many hydrogen bonds can bind more strongly to the enzyme's active site [45]. The interaction between the ligand and the target amino acid residue is stronger and more stable when the hydrogen bond distance gets closer [49]. The test ligand with a high ΔG_{bind} value is epicatechin with four hydrogen and seven hydrophobic interactions. The value of ΔG_{bind} is inversely proportional to the value of the inhibition constant (K_i). The more negative the ΔG_{bind} value, the lower the K_i value. When the value of K_i gets lower, lower concentrations of ligand would be required to inhibit the activity of the enzyme [50].

4. Conclusion

Cinnamon has potential as an alternative treatment for Alzheimer's related to the mechanism of inhibition of the AChE enzyme. Based on the in silico method, epicatechin, medioresinol, and gamma eudesmol compounds were predicted to bind almost as strongly as the reference ligand donepezil. However, these compounds are not potentially better than donepezil. The inhibition of AChE by epicatechin was dominated by

hydrogen bonding with more enzyme active sites than other compounds, whereas medioresinol was dominated by hydrophobic bonds. Epicatechin has the best potential among other compounds in cinnamon for Alzheimer's treatment because it has the most negative affinity compared to other compounds and the lowest K_i value. In addition, epicatechin has dual binding to AChE, namely CAS and PAS.

Acknowledgment

The authors would like to thank the Indonesian Collaborative Research-WCU (World Class University) Fiscal Year 2020 Number: 1755/IT3.L1/PN/2020/IT3.L1/PN/2020 on behalf of Dr. Mega Safithri, S.Si., M.Si which has assisted in funding this article.

References

- [1] Indu Bhushan, Manjot Kour, Guneet Kour, Shriya Gupta, Supriya Sharma, Arvind Yadav, Alzheimer's disease: Causes & treatment-A review, *Annals of Biotechnology*, 1, 1, (2018), 1-8 <http://dx.doi.org/10.33582/2637-4927/1002>
- [2] Anil Kumar Singhal, Vijay Naithani, Om Prakash Bangar, Medicinal plants with a potential to treat Alzheimer and associated symptoms, *International Journal of Nutrition, Pharmacology, Neurological Diseases*, 2, 2, (2012), 84-91 <https://doi.org/10.4103/2231-0738.95927>
- [3] Alzheimer's Disease International, *World Alzheimer Report 2021. Journey through the diagnosis of dementia*, Alzheimer's Disease International, London, 2021
- [4] Alzheimer's Indonesia, *Statistik tentang demensia*, 2019
- [5] Begüm Nurpelin Sağlık, Serkan Levent, Derya Osmaniye, Ulviye Acar Çevik, Betül Kaya Çavuşoğlu, Yusuf Özkay, Ali Savaş Koparal, Zafer Asım Kaplancıklı, Design, synthesis, and biological activity evaluation of new donepezil-like compounds bearing thiazole ring for the treatment of Alzheimer's disease, *Crystals*, 10, 8, (2020), 637 <https://doi.org/10.3390/cryst10080637>
- [6] Jagmohan Sharma, K. Ramanathan, Rao Sethumadhavan, Identification of potential inhibitors against acetylcholinesterase associated with Alzheimer's diseases: a molecular docking approach, *Journal of Computational Methods in Molecular Design*, 1, 1, (2011), 44-51
- [7] Kamlesh Sharma, Cholinesterase inhibitors as Alzheimer's therapeutics (Review), *Molecular Medicine Reports*, 20, 2, (2019), 1479-1487 <https://doi.org/10.3892/mmr.2019.10374>
- [8] Mery Budiarti, Wahyu Jokopriambodo, Ani Isnawati, Karakterisasi minyak atsiri dari simplisia basah ranting dan daun sebagai alternatif substitusi kulit batang *cinnamomum burmannii* blume, *Jurnal Kefarmasian Indonesia*, (2018), 125-136 <https://doi.org/10.22435/jki.v8i2.323>
- [9] Aleix Gimeno, María José Ojeda-Montes, Sarah Tomás-Hernández, Adrià Cereto-Massagué, Raúl Beltrán-Debón, Miquel Mulero, Gerard Pujadas, Santiago Garcia-Vallvé, The light and dark sides of virtual screening: what is there to know?, *International Journal of Molecular Sciences*, 20, 6, (2019), 1-24 <https://doi.org/10.3390/ijms20061375>

- [10] Eduardo Habib Bechelane Maia, Letícia Cristina Assis, Tiago Alves De Oliveira, Alisson Marques Da Silva, Alex Gutterres Taranto, Structure-based virtual screening: from classical to artificial intelligence, *Frontiers in Chemistry*, 8, (2020), 343 <https://doi.org/10.3389/fchem.2020.00343>
- [11] Fauzan Zein Muttaqin, Wayan Ayu Puje Astuti, Ellin Febrina, Aiyi Asnawi, Penapisan Virtual Berbasis Struktur dari Database Bahan Alam Zinc Sebagai Inhibitor Bruton Tyrosine Kinase, *Jurnal Ilmiah Ibnu Sina*, 4, 2, (2019), 400–409
- [12] Madhu Katyayani Balijepalli, Ayuba Sunday Buru, Raghavendra Sakirolla, Mallikarjuna Rao Pichika, Cinnamomum genus: A review on its biological activities, *International Journal of Pharmacy and Pharmaceutical Sciences*, 9, 2, (2017), 1–11
- [13] Edward J. Okello, Joshua Mather, Comparative kinetics of acetyl- and butyryl-cholinesterase inhibition by green tea catechins: relevance to the symptomatic treatment of Alzheimer's disease, *Nutrients*, 12, 4, (2020), 1090 <https://doi.org/10.3390/nu12041090>
- [14] Helen M. Berman, John Westbrook, Zukang Feng, Gary Gilliland, Talapady N. Bhat, Helge Weissig, Ilya N. Shindyalov, Philip E. Bourne, The protein data bank, *Nucleic Acids Research*, 28, 1, (2000), 235–242 <https://doi.org/10.1093/nar/28.1.235>
- [15] Minky Son, Chanin Park, Shailima Rampogu, Amir Zeb, Keun Woo Lee, Discovery of novel acetylcholinesterase inhibitors as potential candidates for the treatment of Alzheimer's disease, *International Journal of Molecular Sciences*, 20, 4, (2019), 1–15 <https://doi.org/10.3390/ijms20041000>
- [16] Muhammad Fakhri, Yuni Rahmayanti, Potensi Fitokimia *Citrus Aurantium* (*Hesperetin*, *Naringenin*) dalam Menghambat Xantin Oksidase Pada Hiperurisemia Secara In Silico, *Jurnal Health Sains*, 2, 1, (2021), 79–89
- [17] Garrett M. Morris, Ruth Huey, William Lindstrom, Michel F. Sanner, Richard K. Belew, David S. Goodsell, Arthur J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, *Journal of Computational Chemistry*, 30, 16, (2009), 2785–2791 <https://doi.org/10.1002/jcc.21256>
- [18] Roman A. Laskowski, Malcolm W. MacArthur, David S. Moss, Janet M. Thornton, PROCHECK: a program to check the stereochemical quality of protein structures, *Journal of Applied Crystallography*, 26, 2, (1993), 283–291 <https://doi.org/10.1107/S0021889892009944>
- [19] Christopher A. Lipinski, Lead- and drug-like compounds: the rule-of-five revolution, *Drug Discovery Today: Technologies*, 1, 4, (2004), 337–341 <https://doi.org/10.1016/j.ddtec.2004.11.007>
- [20] Peter Juma Ochieng, Tony Sumaryada, Daniel Okun, Molecular docking and pharmacokinetic prediction of herbal derivatives as maltase-glucoamylase inhibitor, *Asian Journal of Pharmaceutical and Clinical Research*, 10, 9, (2017), 392–398 <https://doi.org/10.22159/ajpcr.2017.v10i9.19337>
- [21] Oleg Trott, Arthur J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, *Journal of Computational Chemistry*, 31, 2, (2010), 455–461 <https://doi.org/10.1002/jcc.21334>
- [22] Christopher Llynard D. Ortiz, Gladys C. Completo, Ruel C. Nacario, Ricky B. Nellas, Potential inhibitors of galactofuranosyltransferase 2 (GlfT2): Molecular docking, 3D-QSAR, and in silico ADMETox Studies, *Scientific Reports*, 9, 1, (2019), 1–28 <https://doi.org/10.1038/s41598-019-52764-8>
- [23] Jonah Cheung, Ebony N. Gary, Kazuro Shiomi, Terrone L. Rosenberry, Structures of human acetylcholinesterase bound to dihydrotanshinone I and territrem B show peripheral site flexibility, *ACS Medicinal Chemistry Letters*, 4, 11, (2013), 1091–1096 <https://doi.org/10.1021/ml400304w>
- [24] Changdev G. Gadhe, Anand Balupuri, Seung Joo Cho, In silico characterization of binding mode of CCR8 inhibitor: homology modeling, docking and membrane based MD simulation study, *Journal of Biomolecular Structure and Dynamics*, 33, 11, (2015), 2491–2510 <https://doi.org/10.1080/07391102.2014.1002006>
- [25] Bosco K. Ho, Robert Brasseur, The Ramachandran plots of glycine and pre-proline, *BMC Structural Biology*, 5, 1, (2005), 1–11 <https://doi.org/10.1186/1472-6807-5-14>
- [26] Oliviero Carugo, K. Djinović-Carugo, Half a century of Ramachandran plots, *Acta Crystallographica Section D: Biological Crystallography*, 69, 8, (2013), 1333–1341 <https://doi.org/10.1107/S0907444491301158X>
- [27] Gita Syahputra, Simulasi docking kurkumin enol, bisdemetoksikurkumin dan analognya sebagai inhibitor enzim 12-lipoksigenase, *Jurnal Biofisika*, 10, 1, (2014), 55–67
- [28] Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy, Paul J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, *Advanced Drug Delivery Reviews*, 23, 1–3, (1997), 3–25 [https://doi.org/10.1016/S0169-409X\(00\)00129-0](https://doi.org/10.1016/S0169-409X(00)00129-0)
- [29] Xiaochun Wu, Lloyd R. Whitfield, Barbara H. Stewart, Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter, *Pharmaceutical Research*, 17, 2, (2000), 209–215 <https://doi.org/10.1023/A:1007525616017>
- [30] Violeta Ivanović, Miroslav Rančić, Biljana Arsić, Aleksandra Pavlović, Lipinski's rule of five, famous extensions and famous exceptions, *Chemia Naissensis*, 3, 1, (2020), 171–177
- [31] Loita Datu Nindita, Modeling Hubungan Kuantitatif Struktur Dan Aktivitas (HKSA) Pinocembrin Dan Turunannya Sebagai Anti Kanker modelling a Quantitative Structure and Activity Relationship (QSAR) in Pinocembrin and Its Derivative as the Anti-Cancer, *UNESA Journal of Chemistry*, 3, 2, (2014), 26–34
- [32] Shawn M. Lamothe, Jun Guo, Wentao Li, Tonghua Yang, Shetuan Zhang, The human ether-a-go-go-related gene (hERG) potassium channel represents an unusual target for protease-mediated damage, *Journal of Biological Chemistry*, 291, 39, (2016), 20387–20401 <https://doi.org/10.1074/jbc.M116.743138>

- [33] James E. Klaunig, Chemical Carcinogenesis, in: C.D. Klaassen (Ed.) *Casarett and Doull's Toxicology: The Basic Science of Poisons (8th edition)*, McGraw-Hill Education, New York, 2013
- [34] Vincent James Cogliano, Robert Baan, Kurt Straif, Yann Grosse, Béatrice Lauby-Secretan, Fatiha El Ghissassi, Véronique Bouvard, Lamia Benbrahim-Tallaa, Neela Guha, Crystal Freeman, Laurent Galichet, Christopher P. Wild, Preventable Exposures Associated With Human Cancers, *JNCI: Journal of the National Cancer Institute*, 103, 24, (2011), 1827–1839 <https://doi.org/10.1093/jnci/djr483>
- [35] Yesi Astri, Truly Sitorus, Joseph I. Sigit, Muchtan Sujatno, Toksisitas Akut per Oral Ekstrak Etanol Daun Dewa (*Gynura pseudochina* (Lour.) DC) terhadap Kondisi Lambung Tikus Jantan dan Betina Galur Wistar, *Majalah Kedokteran Bandung*, 44, 1, (2012), 38–43 <http://dx.doi.org/10.15395/mkb.v44n1.71>
- [36] Dave Eaton, Steven G. Gilbert, Principles of Toxicology, in: C.D. Klaassen (Ed.) *Casarett & Doull's Toxicology: The Basic Science of Poisons (8th edition)*, McGraw-Hill Education, New York, 2013
- [37] Xiao Li, Lei Chen, Feixiong Cheng, Zengrui Wu, Hanping Bian, Congying Xu, Weihua Li, Guixia Liu, Xu Shen, Yun Tang, In silico prediction of chemical acute oral toxicity using multi-classification methods, *Journal of Chemical Information and Modeling*, 54, 4, (2014), 1061–1069 <https://doi.org/10.1021/ci5000467>
- [38] J. Christian Baber, David C. Thompson, Jason B. Cross, Christine Humblet, GARD: a generally applicable replacement for RMSD, *Journal of Chemical Information and Modeling*, 49, 8, (2009), 1889–1900 <https://doi.org/10.1021/ci9001074>
- [39] Nursamsiar Nursamsiar, Maya M. Mangande, Akbar Awaluddin, Syamsu Nur, Aiyi Asnawi, In Silico Study of Aglycon Curculigoside A and Its Derivatives as α -Amilase Inhibitors, *Indonesian Journal of Pharmaceutical Science and Technology*, 7, 1, (2020), 29–37 <https://doi.org/10.24198/ijpst.v7i1.23062>
- [40] Mohd Ahmar Rauf, Swaleha Zubair, Asim Azhar, Ligand docking and binding site analysis with PyMOL and Autodock/Vina, *International Journal of Basic and Applied Sciences*, 4, 2, (2015), 168 <https://doi.org/10.1007/s10822-010-9352-6>
- [41] Syed Sikander Azam, Sumra Wajid Abbasi, Molecular docking studies for the identification of novel melatonergic inhibitors for acetylserotonin-O-methyltransferase using different docking routines, *Theoretical Biology and Medical Modelling*, 10, 1, (2013), 1–16 <https://doi.org/10.1186/1742-4682-10-63>
- [42] Shibaji Ghosh, Kalyanashis Jana, Bishwajit Ganguly, Revealing the mechanistic pathway of cholinergic inhibition of Alzheimer's disease by donepezil: a metadynamics simulation study, *Physical Chemistry Chemical Physics*, 21, 25, (2019), 13578–13589 <https://doi.org/10.1039/C9CP02613D>
- [43] Danna De Boer, Nguyet Nguyen, Jia Mao, Jessica Moore, Eric J. Sorin, A comprehensive review of cholinesterase modeling and simulation, *Biomolecules*, 11, 4, (2021), 1–35 <https://doi.org/10.3390/biom11040580>
- [44] Mariyana Atanasova, Nikola Yordanov, Ivan Dimitrov, Strahil Berkov, Irini Doytchinova, Molecular docking study on galantamine derivatives as cholinesterase inhibitors, *Molecular Informatics*, 34, 6–7, (2015), 394–403 <https://doi.org/10.1002/minf.201400145>
- [45] Rollando Rollando, Pendekatan Struktur Aktivitas dan Penambatan Molekul Senyawa 2-iminoethyl 2-(2-(1-hydroxypentan-2-yl) phenyl) acetate Hasil Isolasi Fungi Endofit Genus *Fusarium* sp pada Enzim β -ketoasil-ACP KasA Sintase, *Pharmaceutical Journal of Indonesia*, 3, 2, (2018), 45–51 <http://dx.doi.org/10.21776/ub.pji.2017.003.02.2>
- [46] George A. Jeffrey, *An introduction to hydrogen bonding*, Oxford University Press New York, 1997
- [47] Thomas Balle, Tommy Liljefors, Molecular Recognition, in: K. Stromgaard, P. Krosggaard-Larsen, U. Madsen (Eds.) *Textbook of Drug Design and Discovery (5th edition)*, 2017
- [48] Yaghoob Pourshojaei, Ardavan Abiri, Razieh Eskandari, Fatemeh Dourandish, Khalil Eskandari, Ali Asadipour, Synthesis, biological evaluation, and computational studies of novel fused six-membered O-containing heterocycles as potential acetylcholinesterase inhibitors, *Computational Biology and Chemistry*, 80, (2019), 249–258 <https://doi.org/10.1016/j.compbiolchem.2019.04.004>
- [49] Arwansyah Arwansyah, Laksmi Ambarsari, Tony I. Sumaryada, Simulasi docking senyawa kurkumin dan analognya sebagai inhibitor reseptor androgen pada kanker prostat, *Current Biochemistry*, 1, 1, (2014), 11–19
- [50] Doni Dermawan, Riyadi Sumirtanurdin, Deti Dewantisari, Molecular Dynamics Simulation Estrogen Receptor Alpha againts Andrographolide as Anti Breast Cancer, *Indonesian Journal of Pharmaceutical Science and Technology*, 6, 2, (2019), 65–76 <https://doi.org/10.24198/ijpst.v6i2.18168>